Subtopic Deep Dive
Gene Fusions in Fibrous Tumors
Research Guide
What is Gene Fusions in Fibrous Tumors?
Gene fusions in fibrous tumors are recurrent genetic rearrangements, such as NAB2-STAT6 in solitary fibrous tumor and ALK fusions in inflammatory myofibroblastic tumor, that define specific diagnostic entities among soft tissue neoplasms.
Molecular studies identified NAB2-STAT6 fusions in solitary fibrous tumor (Robinson et al., 2013, 796 citations) and MYH9-USP6 in nodular fasciitis (Erickson-Johnson et al., 2011, 393 citations). STAT6 nuclear expression serves as an immunohistochemical surrogate for NAB2-STAT6 (Doyle et al., 2013, 751 citations). Over 20 papers document fusions like PDGFRB rearrangements and ALK-CLTC in fibrous tumors.
Why It Matters
Gene fusions enable precise classification of fibrous tumors with histologic overlap, guiding targeted therapies like ALK inhibitors for inflammatory myofibroblastic tumor (Cessna et al., 2002; Bridge et al., 2001). NAB2-STAT6 detection refines solitary fibrous tumor risk stratification (Demicco et al., 2017). The 2020 WHO classification integrates these fusions for standardized diagnostics (Sbaraglia et al., 2020). Fusion-specific tests via NGS and FISH improve patient outcomes in sarcoma management.
Key Research Challenges
Fusion Detection Sensitivity
NGS and FISH methods vary in sensitivity for low-prevalence fusions like PDGFRB rearrangements. Histologic mimics complicate interpretation (Doyle et al., 2013). Standardization across labs remains inconsistent (Sbaraglia et al., 2020).
Risk Stratification Variability
NAB2-STAT6 fusion variants correlate inconsistently with metastasis risk in solitary fibrous tumor. Models require validation across cohorts (Demicco et al., 2017). Clinical integration lags behind molecular findings.
Therapeutic Targeting Gaps
ALK fusions respond to inhibitors, but NAB2-STAT6 lacks direct drugs. Rare fusions like MYH9-USP6 challenge drug development (Erickson-Johnson et al., 2011). Trial data for fibrous tumors remain limited (Gleason and Hornick, 2007).
Essential Papers
The 2020 WHO Classification of Soft Tissue Tumours: news and perspectives
Marta Sbaraglia, Elena Bellan, Angelo Paolo Dei Tos · 2020 · Pathologica · 925 citations
Mesenchymal tumours represent one of the most challenging field of diagnostic pathology and refinement of classification schemes plays a key role in improving the quality of pathologic diagnosis an...
Identification of recurrent NAB2-STAT6 gene fusions in solitary fibrous tumor by integrative sequencing
Dan R. Robinson, Yi-Mi Wu, Shanker Kalyana‐Sundaram et al. · 2013 · Nature Genetics · 796 citations
Nuclear expression of STAT6 distinguishes solitary fibrous tumor from histologic mimics
Leona A. Doyle, Marina Vivero, Christopher D.�M. Fletcher et al. · 2013 · Modern Pathology · 751 citations
Inflammatory myofibroblastic tumours: where are we now?
Briana C. Gleason, Jason L. Hornick · 2007 · Journal of Clinical Pathology · 735 citations
Inflammatory pseudotumour is a generic term applied to a variety of neoplastic and non-neoplastic entities that share a common histological appearance, namely a cytologically bland spindle cell pro...
Risk assessment in solitary fibrous tumors: validation and refinement of a risk stratification model
Elizabeth G. Demicco, Michael J. Wagner, Robert G. Maki et al. · 2017 · Modern Pathology · 411 citations
Nodular fasciitis: a novel model of transient neoplasia induced by MYH9-USP6 gene fusion
Michele R. Erickson‐Johnson, Margaret M. Chou, Barbara R. Evers et al. · 2011 · Laboratory Investigation · 393 citations
An update on the management of sporadic desmoid-type fibromatosis: a European Consensus Initiative between Sarcoma PAtients EuroNet (SPAEN) and European Organization for Research and Treatment of Cancer (EORTC)/Soft Tissue and Bone Sarcoma Group (STBSG)
B. Kasper, Christina Baumgarten, J. Santiago García et al. · 2017 · Annals of Oncology · 388 citations
Reading Guide
Foundational Papers
Read Robinson et al. (2013) first for NAB2-STAT6 discovery via sequencing; Doyle et al. (2013) next for IHC validation; Gleason and Hornick (2007) for inflammatory myofibroblastic tumor overview.
Recent Advances
Study Sbaraglia et al. (2020) for WHO updates; Demicco et al. (2017) for risk models; Kasper et al. (2017) for desmoid management context.
Core Methods
NGS for fusion discovery (Robinson et al., 2013); IHC for STAT6/ALK (Doyle et al., 2013; Cessna et al., 2002); FISH for rearrangements (Bridge et al., 2001).
How PapersFlow Helps You Research Gene Fusions in Fibrous Tumors
Discover & Search
Research Agent uses searchPapers and exaSearch to find NAB2-STAT6 fusion papers, then citationGraph on Robinson et al. (2013) reveals 796 citing works including Doyle et al. (2013) and Demicco et al. (2017). findSimilarPapers expands to ALK fusions in inflammatory myofibroblastic tumor.
Analyze & Verify
Analysis Agent applies readPaperContent to extract fusion breakpoints from Robinson et al. (2013), verifies claims with CoVe against Gleason and Hornick (2007), and runs PythonAnalysis to plot STAT6 expression data frequencies across 135 cases (Cessna et al., 2002) with GRADE scoring for evidence strength.
Synthesize & Write
Synthesis Agent detects gaps in NAB2-STAT6 therapy via contradiction flagging between Demicco et al. (2017) and Sbaraglia et al. (2020); Writing Agent uses latexEditText, latexSyncCitations for 10-paper review, and latexCompile for diagnostic flowchart with exportMermaid diagrams of fusion pathways.
Use Cases
"Analyze fusion frequencies in 135 inflammatory myofibroblastic tumor cases from Cessna et al."
Analysis Agent → readPaperContent → runPythonAnalysis (pandas to tabulate ALK1/p80 positivity rates) → GRADE-verified CSV export of 85% ALK expression stats.
"Draft LaTeX review of NAB2-STAT6 diagnostics citing Robinson and Doyle."
Synthesis Agent → gap detection → Writing Agent → latexEditText + latexSyncCitations (10 papers) → latexCompile → PDF with fusion diagram via exportMermaid.
"Find GitHub repos analyzing USP6 fusions from Erickson-Johnson paper."
Research Agent → paperExtractUrls (Erickson-Johnson et al., 2011) → paperFindGithubRepo → githubRepoInspect → code snippets for MYH9-USP6 simulation.
Automated Workflows
Deep Research workflow scans 50+ papers on fibrous fusions via searchPapers → citationGraph → structured report with GRADE tables on NAB2-STAT6 variants. DeepScan applies 7-step CoVe to verify ALK inhibitor efficacy claims from Cessna et al. (2002) against Bridge et al. (2001). Theorizer generates hypotheses linking USP6 fusions to transient neoplasia models (Erickson-Johnson et al., 2011).
Frequently Asked Questions
What defines gene fusions in fibrous tumors?
Recurrent fusions like NAB2-STAT6 in solitary fibrous tumor (Robinson et al., 2013) and ALK-CLTC in inflammatory myofibroblastic tumor (Bridge et al., 2001) distinguish entities via NGS or IHC surrogates like STAT6 nuclear expression (Doyle et al., 2013).
What are main detection methods?
Integrative sequencing identifies NAB2-STAT6 (Robinson et al., 2013); FISH/NGS detect ALK (Cessna et al., 2002); STAT6 IHC serves as surrogate (Doyle et al., 2013).
What are key papers?
Robinson et al. (2013, 796 citations) discovered NAB2-STAT6; Doyle et al. (2013, 751 citations) validated STAT6 IHC; Sbaraglia et al. (2020, 925 citations) integrated into WHO classification.
What open problems exist?
Therapeutics for NAB2-STAT6 lack progress; risk models for fusion variants need refinement (Demicco et al., 2017); rare fusions like MYH9-USP6 require expanded cohorts (Erickson-Johnson et al., 2011).
Research Soft tissue tumor case studies with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Gene Fusions in Fibrous Tumors with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers
Part of the Soft tissue tumor case studies Research Guide